Efficacy and safety of neoadjuvant chemotherapy versus neoadjuvant concurrent radiochemotherapy for resectable esophageal squamous cell carcinoma: a meta-analysis / 中华胸心血管外科杂志
Chinese Journal of Thoracic and Cardiovascular Surgery
;
(12): 526-532, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-912318
ABSTRACT
Objective:
To systematic review the clinical efficacy and safety of neoadjuvant chemotherapy and neoadjuvant concurrent chemoradiotherapy for resectable esophageal squamous cell carcinoma.Methods:
Literature search was performed from Web of Science, Pubmed, Cochrane Library, Embase, CBM, Wanfang Data, CNKI and Chongqing VIP. The clinical controlled studies of neoadjuvant chemotherapy versus neoadjuvant concurrent chemoradiation in the treatment of resectable esophageal squamous cell carcinoma was searched. Relevant outcome indicators were analyzed by Revman 5.3 statistical software.Results:
Nine studies were included, with a total of 1, 369 patients. Compared with the neoadjuvant chemoradiotherapy, the neoadjuvant chemotherapy had lower overall survival rates at 3 and 5 years( OR=0.68, 95% CI 0.53-0.86, P<0.05; OR=0.51, 95% CI 0.34-0.77, P<0.05) , lower pathological complete remission rate( OR=0.28, 95% CI 0.18-0.45, P<0.05)and R0 resection rate( OR=0.39, 95% CI 0.22-0.68, P<0.05), The total postoperative complication rate is similar( OR=1.07, 95% CI 0.75-1.51, P>0.05).Conclusion:
Neoadjuvant concurrent radiochemotherapy maybe superior to neoadjuvant chemotherapy among patients with resectable esophageal squamous cell carcinoma.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Revisiones Sistemáticas Evaluadas
Idioma:
Chino
Revista:
Chinese Journal of Thoracic and Cardiovascular Surgery
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS